NCT05621343Completed
New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
Current diagnostic tools such as interferon gamma release assay (IGRA) and purified protein derivative (PPD) can not distinguish patients with latent tuberculosis infection (LTBI) and persistence of live mycobacteria. This inability to rule out living mycobacteria in patients investigated for LTBI leads to unnecessary and potentially harmful treatment regimes all around the globe. The goal of this observational study is to identify candidate biomarkers for viable bacilli in latent tuberculosis in order to decrease the use of unnecessary and ineffective antibiotic treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 89 (actual)
- First submitted
- 10 Nov 2022
- Start date
- 21 Dec 2021
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Region Skane
- Diseases
- Tuberculosis
- NCT number
- NCT05621343
What you commit to
- Study type: Observational
- Participants enrolled: 89
- From 21 Dec 2021 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous treatment for either active or latent TB infection
- Controls
- previous treatment for either active or latent TB infection
- Active TB
Other illness
- active tuberculosis
- chronic illness
- latent- OR active tuberculosis
- chronic illness
Age
- age \< 15 years
Other
- immunosuppressive treatment
- pregnancy (including 6 months post-partum)
- immunosuppressive treatment
- pregnancy (including 6 months post-partum)
Who the study is looking for
- latent tuberculosis: Interferon gamma (IFN-γ) \>0.70 IU/ml in the Quantiferon-TB Plus assay
- age 15-25 years OR high likelihood of recent TB transmission
- informed consent
- age 15-25 years
- informed consent
- diagnosed with active TB
- informed consent
Criteria the registry did not label
- LTBI (2 groups)
Age in the registry: 15 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Skåne University Hospital Coordinator of this site? Confirm its status | Malmö | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.